Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin, DMT, and Methylone Studies; RAND Polling Reveals 23% of Americans Support Legal Psilocybin Use
- Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out
- New State Bills and Progress Updates
- Congressional Appropriations Bills Include Language on Psychedelic Therapy, Rollout
- Colorado Moves Toward Real-World Outcomes Tracking
- RAND Survey: Americans Divided on Psilocybin Legalisation
- New Publications: DMT, Methylone, and Germany’s State-Funded Psilocybin Trial
- Helus’ Phase 2a Study of Intravenous DMT in MDD Published in Nature Medicine
- Transcend’s Phase 2 Study of Methylone in PTSD Publishes in JAMA Psychiatry
- Large German Psilocybin Trial Misses Primary Endpoint
- Other Stories
- Latest Data from Australia Reports 188 Patients Treated by Year-End 2025
- Prasad and Makary Discuss FDA’s ‘One Pivotal Trial’ New Normal
- Redditors Discuss Spravato Dosing Frequency, Working Arrangements
- More Headlines
Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out
Here, we provide a policy round-up: from state bill updates through to psychedelics’ appearances in Congressional appropriations bills and developments in Colorado’s Natural Medicine Program.
New State Bills and Progress Updates
You can remain current on psychedelics-related bills at the state and federal level in the U.S. by using our new Pα+ Psychedelic Bill Tracker, which, at the time of writing, catalogues around eighty bills. What’s more, for the first few months of the year, we will share a monthly round-up: you can read January’s here.
Here, we are sharing new bills that have been introduced since our last update in Bulletin 219:
- Connecticut SB00191 would make certain modifications to the state’s psychedelic-assisted therapy program.
- West Virginia SB906 is a trigger law bill that would...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks